Daily Medication Pearl: Empagliflozin and Linagliptin (Glyxambi)

Indication: Empagliflozin and linagliptin (Glyxambi)is a sodium-glucose co-transporter 2 (SGLT2) inhibitor and dipeptidyl peptidase-4 (DPP-4) inhibitor combination product indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both empagliflozin and linagliptin is appropriate.

Insight:

• Dosing: The recommended dose of Glyxambi is 10 mg empagliflozin/5 mg linagliptin once daily, taken in the morning, with or without food.
• Dosage forms: 10 mg empagliflozin/5 mg linagliptin, 25 mg empagliflozin/5 mg linagliptin
• Adverse events: The most common adverse reactions associated with Glyxambi (a 5% or greater incidence) were urinary tract infections, nasopharyngitis, and upper respiratory tract infections.
• Mechanism of action: Glyxambi combines 2 antihyperglycemic agents with complementary mechanisms of action to improve glycemic control in patients with type 2 diabetes: empagliflozin, a SGLT2 inhibitor, and linagliptin, a dipeptidyl peptidase-4 DPP-4 inhibitor.
• Manufacturer: Boehringer Ingelheim

Sources:

LABEL (fda.gov)

glyxambi image - Google Search